Pericarditis as an interdisciplinary problem. In anticipation of the update of the European Society of Cardiology guidelines
https://doi.org/10.47360/1995-4484-2024-365-368
Abstract
Pericarditis is one of the most common forms of inflammatory diseases of the cardiovascular system, diseases that are observed in cardiology, immunology and rheumatology. Anti-inflammatory therapy is the mainstay of treatment for pericarditis. Low recommendations for the diagnosis and treatment of pericarditis for about 10 years, and in 2025, guide their next update. Professor Massimo Imasio, who is a member of the Working Group on Diagnosis and Various Diseases of the Pericardium of the European Society of Cardiology (ESC, European Society of Cardiology) and the Association of Cardiothoracic Surgery (EACTS, European Association of Cardiothoracic Surgery) 2015 and Chairman of the 2025 ESC Working Guidelines on Myocarditis and Pericarditis, gave an interview regarding the most pressing issues in the diagnosis and treatment of pericarditis.
About the Authors
Massimo Imazio
Department of Medicine (DMED), University of Udine; Cardiothoracic Department, University Hospital Santa Maria della Misericordia
Italy
Italy
33100, Udine, via Palladio, 8
33100, Udine, Piazzale Santa Maria della Misericordia, 15
Zulfiya N. Sukmarova
V.A. Nasonova Research Institute of Rheumatology
Russian Federation
Russian Federation
115522, Moscow, Kashirskoye Highway, 34A
Evgeny L. Nasonov
V.A. Nasonova Research Institute of Rheumatology; I.M. Sechenov First Moscow State Medical University of the Ministry of Health Care of Russian Federation (Sechenov University)
Russian Federation
Russian Federation
115522, Moscow, Kashirskoye Highway, 34A
119991, Moscow, Trubetskaya str., 8, building 2
References
1. Adler Y, Charron P, Imazio M, Badano L, Barón-Esquivias G, Bogaert J, et al.; ESC Scientific Document Group. 2015 ESC Guidelines for the diagnosis and management of pericardial diseases: The Task Force for the Diagnosis and Management of Pericardial Diseases of the European Society of Cardiology (ESC). Endorsed by: The European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2015;36(42):2921-2964. doi: 10.1093/eurheartj/ehv318
2. Mann DL. The emerging field of cardioimmunology: Past, present and foreseeable future. Circ Res. 2024;134(12):1663-1680. doi: 10.1161/CIRCRESAHA.123.323656
3. Abbate A, Weber B, Garschick M, Adamo L, Beavers C. Inflammation and heart diseases: Immunology, cardiology, and rheumatology. J Cardiovasc Pharmacol. 2024;83(5):361-363. doi: 10.1097/FJC.0000000000001531
4. Imazio M. Medical therapy of pericarditis: tips and tricks for clinical practice. J Cardiovasc Med (Hagerstown). 2024;25(6):420-425. doi: 10.2459/JCM.0000000000001618
5. Furqan MM, Verma BR, Cremer PC, Imazio M, Klein AL. Pericardial diseases in COVID19: A contemporary review. Curr Cardiol Rep. 2021;23(7):90. doi: 10.1007/s11886-021-01519-x
6. Ghantous E, Szekely Y, Lichter Y, Levi E, Taieb P, Banai A, et al. Pericardial involvement in patients hospitalized with COVID-19: Prevalence, associates, and clinical implications. J Am Heart Assoc. 2022;11(7):e024363. doi: 10.1161/JAHA.121.024363
7. Corrao G, Franchi M, Cereda D, Bortolan F, Leoni O, Vignati E, et al. Increased risk of myocarditis and pericarditis and reduced likelihood of severe clinical outcomes associated with COVID19 vaccination: A cohort study in Lombardy, Italy. BMC Infect Dis. 2022;22(1):844. doi: 10.1186/s12879-022-07823-3
8. Xie Y, Xu E, Bowe B, Al-Aly Z. Long-term cardiovascular outcomes of COVID-19. Nat Med. 2022;28(3):583-590. doi: 10.1038/s41591-022-01689-3
9. Sukmarova ZN, Ovchinnikov YuV, Gudima GO, Ibragimova FM, Afonina OV, Machkalyan KE. Hyperechogenic signal from the pericardium after vaccination against SARS-CoV-2. Infectious Diseases. 2021; 19(4):43-50. (In Russ.)]. doi: 10.20953/1729-9225-2021-4-43-50
10. Nasonov EL, Sukmarova ZN, Popkova TV, Belov BS. Problems of immunopathology and prospects for pharmacotherapy of idiopathic recurrent pericarditis: Using an interleukin 1 inhibitor (Anakinra). Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2023;61(1):47-61 (In Russ.)]. doi: 10.47360/1995-4484-2023-47-61
11. Imazio M, Brucato A, Maestroni S, Cumetti D, Dominelli A, Natale G, et al. Prevalence of C-reactive protein elevation and time course of normalization in acute pericarditis: Implications for the diagnosis, therapy, and prognosis of pericarditis. Circulation. 2011;123(10): 1092-1097. doi: 10.1161/CIRCULATIONAHA.110.986372
12. Imazio M. Pericardial involvement in systemic inflammatory diseases. Heart. 2011;97(22):1882-1892. doi: 10.1136/heartjnl-2011-300054
13. Imazio M, Demichelis B, Parrini I, Giuggia M, Cecchi E, Gaschino G, et al. Day-hospital treatment of acute pericarditis: A management program for outpatient therapy. J Am Coll Cardiol. 2004;43(6):1042-1046. doi: 10.1016/j.jacc.2003.09.055
14. Nidorf SM, Eikelboom JW, Budgeon CA, Thompson PL. Lowdose colchicine for secondary prevention of cardiovascular disease. J Am Coll Cardiol. 2013;61(4):404-410. doi: 10.1016/j.jacc.2012.10.027
15. Tardif JC, Kouz S, Waters DD, Bertrand OF, Diaz R, Maggioni AP, et al. Efficacy and safety of low-dose colchicine after myocardial infarction. N Engl J Med. 2019;381(26):2497-2505. doi: 10.1056/NEJMoa1912388
16. Samuel M, Tardif JC, Khairy P, Roubille F, Waters DD, Grégoire JC, et al. Cost-effectiveness of low-dose colchicine after myocardial infarction in the Colchicine Cardiovascular Outcomes Trial (COLCOT). Eur Heart J Qual Care Clin Outcomes. 2021;7(5):486-495. doi: 10.1093/ehjqcco/qcaa045
Review
For citations:
Imazio M., Sukmarova Z.N., Nasonov E.L. Pericarditis as an interdisciplinary problem. In anticipation of the update of the European Society of Cardiology guidelines. Rheumatology Science and Practice. 2024;62(4):365–368. (In Russ.) https://doi.org/10.47360/1995-4484-2024-365-368
Views:
415
Email this article 